An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

Clinical trial NCT05565248 · TERMINATED

Trial details

NCT number: NCT05565248
Sponsor: CRISPR Therapeutics AG
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Disease Endocrine System Diseases Autoimmune Diseases Immune System Diseases

Start date: 2023-01-20
Primary completion: 2025-08-08
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.